Dissecting Acute Drug‐Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver‐On‐A‐Chip Model
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is hallmarked by hepatic steatosis, cell injury, inflammation, and fibrosis. This study elaborates on a multicellular biochip‐based liver sinusoid model to mimic MASLD pathomechanisms and investigate the therapeutic effects of drug candidates lanifibranor and resmetirom. Mouse liver primary hepatocytes, hepatic stellate cells, Kupffer cells, and endothelial cells are seeded in a dual‐chamber biocompatible liver‐on‐a‐chip (LoC). The LoC is then perfused with circulating immune cells (CICs). Acetaminophen (APAP) and free fatty acids (FFAs) treatment recapitulate acute drug‐induced liver injury and MASLD, respectively. As a benchmark for the LoC, multiplex immunofluorescence on livers from APAP‐injected and dietary MASLD‐induced mice reveals characteristic changes on parenchymal and immune cell populations. APAP exposure induces cell death in the LoC, and increased inflammatory cytokine levels in the circulating perfusate. Under FFA stimulation, lipid accumulation, cellular damage, inflammatory secretome, and fibrogenesis are increased in the LoC, reflecting MASLD. Both injury conditions potentiate CIC migration from the perfusate to the LoC cellular layers. Lanifibranor prevents the onset of inflammation, while resmetirom decreases lipid accumulation in hepatocytes and increases the generation of FFA metabolites in the LoC. This study demonstrates the LoC potential for functional and molecular evaluation of liver disease drug candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, we and others recently developed in vitro, mouse primary cell-based models for the study of immune-driving mechanisms of acute liver injuries and, potentially, drug candidate testing in a multicellular environment [351].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [351]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Self-citationImmune surveillance by the liver
Jenne, C. N., & Kubes, P. (2013) · Nature Immunology · doi:10.1038/ni.2691 · Cited by 1,047
Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches
Guilliams, M., Bonnardel, J., Haest, B., Vanderborght, B., Wagner, C., Remmerie, A., Bujko, A., Martens, L., Thoné, T., Browaeys, R., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.018 · Cited by 985
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
Sphingosine 1-phosphate: Lipid signaling in pathology and therapy
Cartier, A., & Hla, T. (2019) · Science · doi:10.1126/science.aar5551 · Cited by 613
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Self-citationHarrison, S. A., Taub, R., Neff, G. W., Lucas, K. J., Labriola, D., Moussa, S. E., Alkhouri, N., & Bashir, M. R. (2023) · Nature Medicine · doi:10.1038/s41591-023-02603-1 · Cited by 435
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337
Mossanen, J. C., Krenkel, O., Ergen, C., Govaere, O., Liepelt, A., Puengel, T., Heymann, F., Kalthoff, S., Lefebvre, E., Eulberg, D., et al. (2016) · Hepatology · doi:10.1002/hep.28682 · Cited by 325
Self-citationSinusoidal communication in liver fibrosis and regeneration
Marrone, G., Shah, V. H., & Gracia-Sancho, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.018 · Cited by 323
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationNonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Self-citationLefere, S., Puengel, T., Hundertmark, J., Penners, C., Frank, A. K., Guillot, A., de Muynck, K., Heymann, F., Adarbes, V., Defrêne, E., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.025 · Cited by 310
Self-citationHepatic microcirculation and mechanisms of portal hypertension
Gracia-Sancho, J., Marrone, G., & Fernández-Iglesias, A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0097-3 · Cited by 274
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Lee, E., Korf, H., & Vidal-Puig, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.024 · Cited by 222
Acetaminophen-induced acute liver injury in mice
Mossanen, J., & Tacke, F. (2015) · Laboratory Animals · doi:10.1177/0023677215570992 · Cited by 181
Self-citationBoyer-Diaz, Z., Aristu-Zabalza, P., Andrés-Rozas, M., Robert, C., Ortega-Ribera, M., Fernández-Iglesias, A., Broqua, P., Junien, J.-L., Wettstein, G., Bosch, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.045 · Cited by 168
Sphingolipid metabolism during Toll‐like receptor 4 (TLR4)‐mediated macrophage activation
Olona, A., Hateley, C., Muralidharan, S., Wenk, M. R., Torta, F. T., & Behmoaras, J. V. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15642 · Cited by 143
Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover
Simón, J., Ouro, A., Ala-Ibanibo, L., Presa, N., Delgado, T. C., & Martínez‐Chantar, M. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010040 · Cited by 134
In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
Understanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116
Self-citationGuillot, A., Winkler, M., Silva Afonso, M., Aggarwal, A., Lopez, D., Berger, H., Kohlhepp, M. S., Liu, H., Özdirik, B., Eschrich, J., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000270 · Cited by 116
Self-citationA global action agenda for turning the tide on fatty liver disease
Lazarus, J. V., Mark, H. E., Allen, A. M., Arab, J. P., Carrieri, P., Noureddin, M., Alazawi, W., Alkhouri, N., Alqahtani, S. A., Anstee, Q. M., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000545 · Cited by 104
Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease
Mitten, E. K., & Baffy, G. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.028 · Cited by 89
Peiseler, M., & Tacke, F. (2021) · Cancers · doi:10.3390/cancers13040730 · Cited by 83
Self-citationNaser, E., Kadow, S., Schumacher, F., Mohamed, Z. H., Kappe, C., Hessler, G., Pollmeier, B., Kleuser, B., Arenz, C., Becker, K. A., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000682 · Cited by 75
Self-citationIn Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations
Kaur, S., Kidambi, S., Ortega-Ribera, M., Thuy, L. T. T., Nieto, N., Cogger, V. C., Xie, W.-F., Tacke, F., & Gracia-Sancho, J. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.11.008 · Cited by 65
Self-citationThe Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer
Gibert‐Ramos, A., Sanfeliu-Redondo, D., Aristu-Zabalza, P., Martínez-Alcocer, A., Gracia‐Sancho, J., Guixé‐Muntet, S., & Fernández‐Iglesias, A. (2021) · Cancers · doi:10.3390/cancers13225719 · Cited by 53
Guillot, A., Kohlhepp, M., Bruneau, A., Heymann, F., & Tacke, F. (2020) · Cancers · doi:10.3390/cancers12092449 · Cited by 46
Self-citationLambrecht, J., & Tacke, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.634409 · Cited by 43
Self-citationThyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110864 · Cited by 42
Self-citationA Comprehensive Analysis of the Glutathione Peroxidase 8 (GPX8) in Human Cancer
Ren, Z., He, Y., Yang, Q., Guo, J., Huang, H., Li, B., Wang, D., Yang, Z., & Tian, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.812811 · Cited by 39
Rezvani, M., Vallier, L., & Guillot, A. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.01.014 · Cited by 34
Self-citationLi, M., Larsen, F. T., van den Heuvel, M. C., Gier, K., Gorter, A. R., Oosterhuis, D., Bijzet, J., de Meijer, V. E., Ravnskjær, K., Nagelkerke, A., et al. (2024) · Nutrients · doi:10.3390/nu16050626 · Cited by 21
Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease
Park, Y., Thadasina, D., Bolujo, I., Isidan, A., Cross-Najafi, A. A., Lopez, K., Li, P., Dahlem, A. M., Kennedy, L. L., Sato, K., et al. (2022) · Seminars in Liver Disease · doi:10.1055/a-1934-5588 · Cited by 15
Mouse models of nonalcoholic steatohepatitis and their application to new drug development
Phung, H. H., & Lee, C. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01410-5 · Cited by 13
Multiplex Immunostaining to Spatially Resolve the Cellular Landscape in Human and Mouse Livers
Guillot, A., Kohlhepp, M. S., & Tacke, F. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3207-9_15 · Cited by 6
Self-citation
Cited by
(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
Guillot, A., & Tacke, F. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000491 · Cited by 45
Self-citationLiu, H., Yin, G., Franco Leonardi, B., Lan, T., Ait Ahmed, Y., Berger, H., Kohlhepp, M. S., Amiridze, N., Martagón Calderón, N., Frau, C., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334425 · Cited by 23
“Based on our in-house tailored LoC system, 23 which we adapted to the present study by introducing BECs, we aimed at modelling the portal multicellular microenvi-(cid:85)(cid:82)(cid:81)(cid:80)(cid:72)(cid:81)(cid:87)(cid”
Self-citationChen, S., Zeng, Q., Cai, X., Xue, J., Yin, G., Song, P., Tang, L., Klein, C., Tacke, F., Guillot, A., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.98362 · Cited by 8
Self-citation
Metadata
- Authors
- Liu, H., Yin, G., Kohlhepp, M. S., Schumacher, F., Hundertmark, J., Hassan, M. I. A., Heymann, F., Puengel, T., Kleuser, B., Mosig, A. S., Tacke, F., & Guillot, A.
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- Freie Universität Berlin (DE)
- Jena University Hospital (DE)
- Corresponding author
- Guillot, Adrien
- ORCID
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2024-06-13
- Volume
- 11
- Issue
- 30
- Pages
- e2403516-e2403516
- ISSN
- 2198-3844 (ISSN-L)
- PMC
- PMC11321671
- OpenAlex
- W4399644705
- Cited by
- 30
- References
- 40
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 5
- FWCI
- 12.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Advanced Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Refubium (Universitätsbibliothek der Freien Universität Berlin) (submittedVersion, cc-by)
- Common Library Network (Der Gemeinsame Bibliotheksverbund) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver (cc-by)
- RWTH Publications (RWTH Aachen)
- Funders
- Bundesministerium für Bildung und Forschung (ImmunAvatar consortium)
- Deutsche Forschungsgemeinschaft (SFB1382, DFGTa434/8‐1, SFB/TRR296, Project‐ID403224013)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- non-alcoholic fatty liver disease, liver-on-a-chip, acetaminophen hepatotoxicity, free fatty acids, hepatic steatosis, lanifibranor, resmetirom, circulating immune cells, Kupffer cells, hepatic stellate cells, hepatocyte lipid accumulation, liver fibrosis, inflammatory cytokines
- MeSH terms
- Acetaminophen, Animals, Disease Models, Animal, Fatty Liver, Liver, Mice, Inbred C57BL, Propionates, Hepatocytes, Chalcones, Mice, Chemical and Drug Induced Liver Injury, Lab-On-A-Chip Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.